WORLDWIDE REGISTRATION
Cabotegravir Long-acting (LA) for PrEP

APPROVAL

US
Australia
Zimbabwe
South Africa

SUBMISSION

Malawi
Botswana
Brazil
Kenya
Uganda
Vietnam
Malaysia
Myanmar
Philippines
China
European Medicines Agency (EMA)
Thailand

✓ “Approval” means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 29 Nov 2022 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.